The encouraging results obtained by the preclinical and the most recent clinical studies suggest that GRPR analogs, and in particular GRPR antagonists, might play in the future an essential role in the diagnosis of prostate cancer at different stages and in the treatment of mCRPC. Here, GRPR is linked to Familial prostate cancer.